What is a primary advantage of second-generation antipsychotics over first-generation antipsychotics?

Choice A reason: Second-generation antipsychotics (SGAs) have a lower affinity for dopamine D2 receptors in the nigrostriatal pathway compared to first-generation antipsychotics. This transient binding or serotonin-dopamine antagonism significantly reduces the incidence of extrapyramidal symptoms such as pseudoparkinsonism, akathisia, and dystonia, which are common with high-potency typical agents. Choice B reason: While SGAs may have a slightly lower profile for inducing neuroleptic malignant syndrome, the risk is not eliminated. NMS remains a rare but potentially fatal idiosyncratic reaction to any dopamine-depleting medication. Therefore, reduced risk of NMS is not considered the primary clinical advantage distinguishing these two classes. Choice C reason: Many second-generation antipsychotics, such as clozapine and olanzapine, possess significant antagonistic activity at muscarinic receptors. This leads to substantial anticholinergic side effects, including xerostomia, blurred vision, urinary retention, and constipation. They do not prevent these effects; in some cases, they exacerbate them more than first-generation drugs. Choice D reason: Broadly speaking, SGAs are not necessarily "more effective" at treating positive psychotic symptoms like hallucinations or delusions than first-generation agents. Their main advantage lies in their superior side-effect profile regarding motor control and their potential, albeit sometimes limited, efficacy in addressing the negative symptoms of schizophrenia.